23 September 2026

ASX Announcement

Firebrick receives $293,000 R&D Tax Incentive

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is pleased to announce that it has received an RDTI (R&D Tax Incentive) payment of $293,000 for eligible R&D expenditure incurred in 2025/26.

The incentive payment related to $673,000 in reported R&D costs in the FY26, associated with the development of new products in the Nasodine range.

“We welcome the valuable injection of non-dilutive funds from the R&D tax incentive” said Dr Peter Molloy, Executive Director of Firebrick Pharma.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

\- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji. Nasodine Nasal Spray was also recently approved for marketing in Indonesia, and the Company is pursuing approval in the Philippines and other markets. Nasodine® Throat Spray is the first follow-on product in the Nasodine range and is now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and expansion of sales to up to 10 markets over three years. For further information, visit firebrickpharma.com

Contacts:

Media contact:
Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:
Kam Watson, Firebrick Pharma
investors@firebrickpharma.com